Levocetirizine

Generic Name: Levocetirizine

Brand Names: Xyzal

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₅ClN_₂O_₃

CAS Number: 130018-77-8

Unique Ingredient Identifier: 6U5EA9RT2O

Background: Levocetirizine is a selective histamine H antagonist used to treat a variety of allergic symptoms. It is the R enantiomer of cetirizine. Levocetirizine has greater affinity for the histamine H receptor than cetirizine.

Levocetirizine was granted FDA approval in 1995.

Indication: Levocetirizine is indicated to treat symptoms of perennial allergic rhinitis and uncomplicated skin manifestations of chronic idiopathic urticaria. It is also used over the counter for a variety of mild allergy symptoms.

Associated Conditions: Allergic Rhinitis (AR), Chronic Idiopathic Urticaria, Common Cold, Nasal Congestion, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis

Associated Therapies: -

Clinical Trials

Clinical Study to Evaluate the Possible Efficacy and Safety of Levocetirizine in Patients With Diabetic Kidney Disease

Phase 2

Recruiting

Conditions: Diabetic Nephropathies

Interventions: Drug: Valsartan 80 mg
Drug: Empagliflozin 10 MG
Drug: Levocetirizine

First Posted Date: 2022-12-06

Last Posted Date: 2024-02-20

Lead Sponsor: Mostafa Bahaa

Target Recruit Count: 60

Registration Number: NCT05638880

Locations: 🇪🇬
Mansoura University, Mansoura, Egypt

A Phase I Study of LY3471851 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3471851
Drug: Placebo
Drug: Levocetirizine

First Posted Date: 2022-10-04

Last Posted Date: 2023-11-18

Lead Sponsor: Nektar Therapeutics

Target Recruit Count: 41

Registration Number: NCT05565729

Locations: 🇺🇸
Covance Dallas, Dallas, Texas, United States

A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)

Phase 3

Recruiting

Conditions: Allergic Asthma

Interventions: Drug: Levocetirizine Dihydrochloride
Drug: Placebo

First Posted Date: 2021-01-07

Last Posted Date: 2024-04-26

Lead Sponsor: Bridgette Jones

Target Recruit Count: 300

Registration Number: NCT04699604

Locations: 🇺🇸
Children's Mercy Hospital, Kansas City, Missouri, United States

Anti-inflammatory H1 Antihistamines Allergic Rhinitis

Phase 4

Completed

Conditions: Allergic Rhinitis

Interventions: Drug: Levocetirizine
Drug: Desloratadine

First Posted Date: 2015-07-24

Last Posted Date: 2015-07-24

Lead Sponsor: Iuliu Hatieganu University of Medicine and Pharmacy

Target Recruit Count: 115

Registration Number: NCT02507635

Phase 1 Study of Levocetirizine

Phase 1

Completed

Conditions: Dermatitis

Interventions: Drug: cetirizine
Drug: placebo
Drug: levocetirizine

First Posted Date: 2015-05-18

Last Posted Date: 2017-08-03

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 20

Registration Number: NCT02447393

Locations: 🇯🇵
GSK Investigational Site, Kagoshima, Japan

Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Neoplasms

Interventions: Drug: Bevacizumab
Drug: Capecitabine
Drug: Levocetirizine

First Posted Date: 2012-11-06

Last Posted Date: 2017-04-20

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 47

Registration Number: NCT01722162

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

Efficacy and Safety of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride in Perennial Allergic Rhinitis (PAR) Patients

Phase 3

Completed

Conditions: Perennial Allergic Rhinitis

Interventions: Drug: Montelukast + Levocetirizine
Drug: Montelukast
Drug: Levocetirizine

First Posted Date: 2012-07-13

Last Posted Date: 2013-04-08

Lead Sponsor: Hanmi Pharmaceutical Company Limited

Target Recruit Count: 283

Registration Number: NCT01640535

Locations: 🇰🇷
Soonchunhyang University Bucheon Hospital, Bucheon, Gyeonggi-do, Korea, Republic of

Pharmacokinetic Study of Levocetirizine Oral Solution

Phase 1

Completed

Conditions: Rhinitis, Allergic, Perennial and Seasonal

Interventions: Drug: Cetirizine
Drug: Levocetirizine

First Posted Date: 2012-06-19

Last Posted Date: 2017-06-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 20

Registration Number: NCT01622283

Locations: 🇯🇵
GSK Investigational Site, Kagoshima, Japan

Bioequivalence Study of Levocetirizine Dihydrochloride Tablets 5 mg Under Fed Condition

Phase 1

Completed

Conditions: Fed

Interventions: Drug: Levocetirizine Dihydrochloride tablets 5 mg
Drug: Levocetirizine Dihydrochloride

First Posted Date: 2012-03-30

Last Posted Date: 2012-12-03

Lead Sponsor: IPCA Laboratories Ltd.

Target Recruit Count: 28

Registration Number: NCT01567501

Locations: 🇮🇳
Accutest Research Lab (I) Pvt. Ltd., Ahmedabad, Gujarat, India

Safety Study of Levocetirizine Oral Solution for Japanese Pediatrics

Phase 3

Completed

Conditions: Rhinitis

Interventions: Drug: Levocetirizine

First Posted Date: 2012-03-26

Last Posted Date: 2017-02-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 60

Registration Number: NCT01563081

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy